Datroway (datopotamab deruxtecan) is the first TROP2-directed therapy approved for advanced lung cancer in the U.S.

Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer.

Diagnosis and treatment of breast cancer can differ for patients in rural communities compared with those in urban ...

A new medication found to reduce the chance of the most common types of breast cancer recurring will be available to many ...

For the first time in Australia, a drug that can delay the growth of tumours is available under the Pharmaceutical Benefits ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab with chemotherapy, achieved ...

You can get in touch with Jack by emailing j.beresford@newsweek.com A new dad captured a heartwarming moment with his infant ...

Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...

ABBV-706 is an ADC targeting SEZ6 developed by AbbVie. It is linked to a topoisomerase 1 inhibitor (TOP1i) via a ...